Lebrikizumab reduced interference of itch on sleep at 52 weeks in patients with moderate-to- severe atopic dermatitis: pooled analysis of two phase 3 randomized controlled trials

被引：0
|
作者：
Yosipovitch, Gil [1 ]
Lio, Peter A. [2 ]
Rosmarin, David [3 ]
Legat, Franz J. [4 ]
Carrascosa, Jose-Manuel [5 ]
Meskimen, Eric [6 ]
Casillas, Marta [6 ]
Pierce, Evangeline [6 ]
Xu, Chenjia [6 ]
Zhong, Jinglin [7 ]
Staender, Sonja [8 ]
机构：
[1] Univ Miami, Miller Sch Med, Coral Gables, FL USA
[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[3] Tufts Univ, Sch Med, Boston, MA USA
[4] Med Univ Graz, Graz, Austria
[5] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
[6] Eli Lilly & Co, Indianapolis, IN USA
[7] IQVIA, Rockville, MD USA
[8] Univ Hosp Munster, Munster, Germany
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
41916
引用
收藏
页码：AB61 / AB61
页数：1
相关论文
共 50 条
  • [31] Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
    Paller, Amy S.
    Flohr, Carsten
    Eichenfield, Lawrence F. F.
    Irvine, Alan D. D.
    Weisman, Jamie
    Soung, Jennifer
    Correia, Ana Pinto
    Natalie, Chitra R. R.
    Capriles, Claudia Rodriguez
    Pierce, Evangeline
    Reifeis, Sarah
    Lima, Renata Gontijo
    Tubau, Clara Armengol
    Laquer, Vivian
    Weidinger, Stephan
    DERMATOLOGY AND THERAPY, 2023, 13 (07) : 1517 - 1534
  • [32] Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
    Amy S. Paller
    Carsten Flohr
    Lawrence F. Eichenfield
    Alan D. Irvine
    Jamie Weisman
    Jennifer Soung
    Ana Pinto Correia
    Chitra R. Natalie
    Claudia Rodriguez Capriles
    Evangeline Pierce
    Sarah Reifeis
    Renata Gontijo Lima
    Clara Armengol Tubau
    Vivian Laquer
    Stephan Weidinger
    Dermatology and Therapy, 2023, 13 (7) : 1517 - 1534
  • [33] Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial
    Merola, Joseph F.
    Sidbury, Robert
    Wollenberg, Andreas
    Chen, Zhen
    Zhang, Annie
    Shumel, Brad
    Rossi, Ana B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (02) : 495 - 497
  • [34] Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials
    Eric L. Simpson
    Dermatology and Therapy, 2017, 7 : 243 - 248
  • [35] Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials
    Simpson, Eric L.
    DERMATOLOGY AND THERAPY, 2017, 7 (02) : 243 - 248
  • [36] Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials
    Simpson, Eric L.
    Merola, Joseph F.
    Silverberg, Jonathan, I
    Reich, Kristian
    Warren, Richard B.
    Staumont-Salle, Delphine
    Girolomoni, Giampiero
    Papp, Kim
    de Bruin-Weller, Marjolein
    Thyssen, Jacob P.
    Zachariae, Rebecca
    Olsen, Christiana K.
    Wollenberg, Andreas
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (06) : 888 - 899
  • [37] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials
    Tofte, Susan J.
    Papp, Kim
    Sadick, Neil
    Bohnert, Krista
    Simpson, Eric
    Thaci, Diamant
    Bieber, Thomas
    Blauvelt, Andrew
    Sofen, Howard
    Gooderham, Melinda
    Chen, Zhen
    Gadkari, Abhijit
    Eckert, Laurent
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2018, 30 (09): : 529 - 541
  • [38] Dupilumab prevents flares in adults with moderate-to-severe atopic dermatitis in a 52-week, randomized, controlled, phase 3 trial
    Merola, J. F.
    Sidbury, R.
    Wollenberg, A.
    Chen, Z.
    Zhang, A.
    Shumel, B.
    Rossi, A. B.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S53 - S53
  • [39] Efficacy and safety of lebrikizumab in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis: a phase III randomized, placebo-controlled trial (ADhere)
    Simpson, Eric L.
    Gooderham, Melinda
    Wollenberg, Andreas
    Weidinger, Stephan
    Armstrong, April
    Soung, Jennifer
    Ferrucci, Silvia
    Lima, Renata Gontijo
    Xu, Wen
    Witte, Michael M.
    Blauvelt, Andrew
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E108 - E108
  • [40] Dupilumab in moderate-to-severe atopic dermatitis: results from two randomized phase 3 trials (SOLO 1 & 2)
    Simpson, E. L.
    Bieber, T.
    Guttman-Yassky, E.
    Beck, L. A.
    Blauvelt, A.
    Cork, M. J.
    Silverberg, J. I.
    Deleuran, M.
    Kataoka, Y.
    Lacour, J. -P.
    Kingo, K.
    Worm, M.
    Poulin, Y.
    Wollenberg, A.
    Soo, Y.
    Graham, N. M. H.
    Pirozzi, G.
    Akinlade, B.
    Staudinger, H.
    Mastey, V.
    Eckert, L.
    Gadkari, A.
    Ardeleanu, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 79 - 79
12345